CN101918443B - 一种与类风湿性关节炎相关的抗原 - Google Patents

一种与类风湿性关节炎相关的抗原 Download PDF

Info

Publication number
CN101918443B
CN101918443B CN2008801231862A CN200880123186A CN101918443B CN 101918443 B CN101918443 B CN 101918443B CN 2008801231862 A CN2008801231862 A CN 2008801231862A CN 200880123186 A CN200880123186 A CN 200880123186A CN 101918443 B CN101918443 B CN 101918443B
Authority
CN
China
Prior art keywords
ser
gly
leu
ala
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801231862A
Other languages
English (en)
Chinese (zh)
Other versions
CN101918443A (zh
Inventor
曼努埃拉·卡斯帕
凯瑟琳·施瓦格尔
伊夫林·特拉赫塞尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philogen SpA
Original Assignee
Philogen SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen SpA filed Critical Philogen SpA
Priority to CN201310233951.9A priority Critical patent/CN103396483B/zh
Publication of CN101918443A publication Critical patent/CN101918443A/zh
Application granted granted Critical
Publication of CN101918443B publication Critical patent/CN101918443B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN2008801231862A 2007-10-30 2008-10-27 一种与类风湿性关节炎相关的抗原 Active CN101918443B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310233951.9A CN103396483B (zh) 2007-10-30 2008-10-27 一种与类风湿性关节炎相关的抗原

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98360607P 2007-10-30 2007-10-30
US60/983,606 2007-10-30
PCT/EP2008/009070 WO2009056268A1 (en) 2007-10-30 2008-10-27 An antigen associated with rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310233951.9A Division CN103396483B (zh) 2007-10-30 2008-10-27 一种与类风湿性关节炎相关的抗原

Publications (2)

Publication Number Publication Date
CN101918443A CN101918443A (zh) 2010-12-15
CN101918443B true CN101918443B (zh) 2013-07-17

Family

ID=40282320

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008801231862A Active CN101918443B (zh) 2007-10-30 2008-10-27 一种与类风湿性关节炎相关的抗原
CN201310233951.9A Active CN103396483B (zh) 2007-10-30 2008-10-27 一种与类风湿性关节炎相关的抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310233951.9A Active CN103396483B (zh) 2007-10-30 2008-10-27 一种与类风湿性关节炎相关的抗原

Country Status (18)

Country Link
US (4) US8222377B2 (enExample)
EP (3) EP2209805B1 (enExample)
JP (3) JP5106635B2 (enExample)
KR (3) KR101836968B1 (enExample)
CN (2) CN101918443B (enExample)
AU (1) AU2008317941B2 (enExample)
BR (1) BRPI0818272B8 (enExample)
CA (1) CA2704296C (enExample)
DK (2) DK3281952T3 (enExample)
ES (2) ES2807753T3 (enExample)
HU (2) HUE050038T2 (enExample)
MX (1) MX2010004726A (enExample)
NO (1) NO2209805T3 (enExample)
PL (2) PL3281952T3 (enExample)
PT (2) PT3281952T (enExample)
RU (2) RU2486198C2 (enExample)
SI (2) SI3281952T1 (enExample)
WO (1) WO2009056268A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070084556A1 (en) 2005-10-14 2007-04-19 Langseder Neal E Method of applying a label to a squeeze tube
MX2009010639A (es) 2007-04-02 2009-10-23 Philogen Spa Nuevo antigeno asociado con la neovasculatura de metastasis tumoral.
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
HUE050038T2 (hu) 2007-10-30 2020-11-30 Philogen Spa Rheumatoid arthritisszel kapcsolatos antigén
EP2379116B1 (en) 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
ES2706428T3 (es) * 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
CA2876285A1 (en) * 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
TWI499426B (zh) * 2012-09-27 2015-09-11 Philogen Spa 與發炎性腸病有關之抗原
US9695232B2 (en) 2012-10-03 2017-07-04 Philogen S.P.A. Anti-ED-A immunoconjugates for inflammatory bowel disease
KR20160117463A (ko) * 2014-02-06 2016-10-10 에프. 호프만-라 로슈 아게 인터루킨-10 면역접합체
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
BR112018000909A2 (pt) 2015-07-16 2018-09-11 Philogen Spa imunoconjugados de il22
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
WO2018224550A1 (en) 2017-06-07 2018-12-13 Philogen S.P.A Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
JP2017197558A (ja) * 2017-06-07 2017-11-02 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
CA3132385A1 (en) * 2019-03-06 2020-09-10 Deka Biosciences, Inc. Il-10 variant molecules and methods of treating inflammatory disease and oncology
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
JP2023534847A (ja) 2020-07-20 2023-08-14 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０を含む二重サイトカイン融合タンパク質
EP4185615A1 (en) 2020-07-22 2023-05-31 Philogen S.p.A. Treatment of pulmonary hypertension
CN113480636B (zh) * 2021-06-23 2023-11-03 烟台科瑞斯生物技术有限责任公司 重组人纤连蛋白及其制备、活性测定和稳定性实验方法
EP4493210A1 (en) 2022-03-17 2025-01-22 Universitätsklinikum Jena Anti-ed-a antibodies for the treatment of pulmonary hypertension
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580859A1 (en) * 1991-03-26 1994-02-02 Otsuka Pharmaceutical Factory, Inc. Anti-eda monoclonal antibody

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) * 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
WO1994017411A1 (en) 1993-01-27 1994-08-04 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
AU2001239470A1 (en) 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
US20030152572A1 (en) * 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
YU17503A (sh) * 2000-09-07 2006-05-25 Schering Aktiengesellschaft Receptor oblasti (ii) edb-fibronektina
US6780594B2 (en) * 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
AU2003282752A1 (en) * 2002-10-08 2004-05-04 Immunomedics, Inc. Antibody therapy
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
CA2523452A1 (en) 2003-04-22 2004-11-04 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
CA2533878A1 (en) 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
JP2007517506A (ja) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
US20060024722A1 (en) 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
JP2008518609A (ja) 2004-11-09 2008-06-05 フィロゲン エスピーエー テネイシンｃに対する抗体
CA2593964A1 (en) * 2004-12-23 2006-06-29 Molmed Spa Conjugation product
KR101281208B1 (ko) * 2005-05-11 2013-07-26 필로겐 에스.피.에이. 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질
EP1893244A4 (en) 2005-06-23 2009-06-24 Univ Emory AGENTS FOR IMAGING
CA2650953A1 (en) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
WO2007128563A1 (en) * 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
MX2009010639A (es) 2007-04-02 2009-10-23 Philogen Spa Nuevo antigeno asociado con la neovasculatura de metastasis tumoral.
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
CA2691218C (en) * 2007-07-25 2018-04-24 Philogen S.P.A. An antigen associated with lung cancers and lymphomas
HUE050038T2 (hu) 2007-10-30 2020-11-30 Philogen Spa Rheumatoid arthritisszel kapcsolatos antigén
AU2009336800A1 (en) 2009-01-07 2011-07-21 Philogen S.P.A. Cancer treatment
EP2379116B1 (en) 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
WO2012041451A1 (en) 2010-09-29 2012-04-05 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
ES2706428T3 (es) 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
US9695232B2 (en) 2012-10-03 2017-07-04 Philogen S.P.A. Anti-ED-A immunoconjugates for inflammatory bowel disease
WO2014174105A1 (en) 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
JP2016519111A (ja) 2013-04-26 2016-06-30 フィロゲン エスピーエー 細胞外マトリックス成分に対する抗体にコンジュゲートしたｉｌ４
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580859A1 (en) * 1991-03-26 1994-02-02 Otsuka Pharmaceutical Factory, Inc. Anti-eda monoclonal antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis;Eveline Trachsel et al.;《Arthritis Research & Therapy》;20070129;第9卷;第1页，摘要 *
Domain antibodies: proteins for therapy;Lucy J. Holt et al.;《TRENDS in Biotechnology》;20031130;第21卷;第484-489页 *

Also Published As

Publication number Publication date
US9556257B2 (en) 2017-01-31
US20190352384A1 (en) 2019-11-21
US10385121B2 (en) 2019-08-20
CA2704296A1 (en) 2009-05-07
PT2209805T (pt) 2017-11-14
DK3281952T3 (da) 2020-08-03
SI3281952T1 (sl) 2020-09-30
US20100260707A1 (en) 2010-10-14
HUE037036T2 (hu) 2018-08-28
EP3281952B1 (en) 2020-06-24
BRPI0818272B8 (pt) 2021-05-25
RU2649368C2 (ru) 2018-04-02
KR20160039305A (ko) 2016-04-08
EP3281952A1 (en) 2018-02-14
JP2015091799A (ja) 2015-05-14
ES2807753T3 (es) 2021-02-24
US20120244114A1 (en) 2012-09-27
PL2209805T3 (pl) 2018-01-31
JP6154594B2 (ja) 2017-06-28
JP5106635B2 (ja) 2012-12-26
PT3281952T (pt) 2020-07-23
MX2010004726A (es) 2010-05-20
SI2209805T1 (sl) 2017-11-30
JP2013040183A (ja) 2013-02-28
AU2008317941B2 (en) 2015-01-22
DK2209805T3 (en) 2017-10-16
KR20180027640A (ko) 2018-03-14
EP2209805A1 (en) 2010-07-28
JP2011502137A (ja) 2011-01-20
CA2704296C (en) 2017-08-22
US8222377B2 (en) 2012-07-17
US20170298122A1 (en) 2017-10-19
BRPI0818272A2 (pt) 2015-04-14
HUE050038T2 (hu) 2020-11-30
CN103396483B (zh) 2016-11-23
KR101608544B1 (ko) 2016-04-01
PL3281952T3 (pl) 2020-11-16
RU2486198C2 (ru) 2013-06-27
BRPI0818272B1 (pt) 2021-01-12
CN101918443A (zh) 2010-12-15
KR101836968B1 (ko) 2018-03-12
KR20100101587A (ko) 2010-09-17
JP6198703B2 (ja) 2017-09-20
WO2009056268A1 (en) 2009-05-07
RU2010121874A (ru) 2011-12-10
KR102002739B1 (ko) 2019-07-23
AU2008317941A1 (en) 2009-05-07
CN103396483A (zh) 2013-11-20
EP2209805B1 (en) 2017-09-06
RU2013115891A (ru) 2014-10-20
NO2209805T3 (enExample) 2018-02-03
EP3783019A1 (en) 2021-02-24
ES2646228T3 (es) 2017-12-12

Similar Documents

Publication Publication Date Title
CN101918443B (zh) 一种与类风湿性关节炎相关的抗原
EP2612869B1 (en) Ed-a antigen of fibrinogen that is associated with lymphomas
US10202442B2 (en) Antigen associated with lung cancers and lymphomas
AU2014274545B2 (en) An antigen associated with rheumatoid arthritis
HK1191353B (en) An antigen associated with rheumatoid arthritis
HK1191353A (en) An antigen associated with rheumatoid arthritis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant